Oncogene:靶向PAT4可有效抑制肿瘤的生长

2015-10-07 sunshine 译 MedSci原创

1

癌细胞存在一种营养传感机制,可帮助其与正常的细胞竞争营养以促进自身的生长。近日,据发表于Oncogene的一项新的研究表明,PAT4是支持癌细胞此机制的蛋白,而靶向针对此蛋白或可抑制癌细胞的生长。


作者解释道,通常癌细胞内存在一些机制可帮助其避开限制而进入机体营养丰富的血液供应区域。

本研究中,研究人员探究了PAT4(一种氨基酸转运蛋白)的作用以支持此机制。研究人员发现,高水平的PAT4与结肠癌患者术后无复发存活率降低有关,此外,研究人员还发现,该联系独立于其他的可影响患者生存率的主要致病因素。

牛津大学生理学解剖学和遗传学系资深作者Dr. Deborah Goberdhan说道:“我们发现侵袭性癌细胞可产生更多的PAT4,使得癌细胞较周围细胞(包括健康的组织)能更好的利用营养。”

本研究中,研究人员还研发了一种抗体,可汇集人体组织样本中的PAT4,研究人员使用此抗体来探究结直肠癌患者的肿瘤样本。

他们发现,PAT4的水平(正如抗体所测定的)与患者癌症的进展有关。癌细胞中PAT4水平较高的患者较PAT4水平较低的患者病情要差,复发和死亡的风险要大。

最后,将人癌组织移植至大鼠体内后,研究人员发现,降低PAT4的水平可减慢肿瘤的生长。

Dr. Goberdhan总结道:“这些研究结果可相互支持。高水平的PAT4意味着一个糟糕的结果,降低其水平可改患者的病情。这意味着,我们确定了一种机制,即癌细胞常用,我们或可靶向治疗将并将其作为联合治疗的一部分。”

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061129, encodeId=77fb206112943, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Wed May 04 02:22:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048684, encodeId=6c55204868412, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Apr 12 21:22:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076655, encodeId=b81e20e665569, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Sep 03 23:22:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558034, encodeId=303e155803400, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Oct 09 10:22:00 CST 2015, time=2015-10-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2061129, encodeId=77fb206112943, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Wed May 04 02:22:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048684, encodeId=6c55204868412, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Apr 12 21:22:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076655, encodeId=b81e20e665569, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Sep 03 23:22:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558034, encodeId=303e155803400, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Oct 09 10:22:00 CST 2015, time=2015-10-09, status=1, ipAttribution=)]
    2016-04-12 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=2061129, encodeId=77fb206112943, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Wed May 04 02:22:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048684, encodeId=6c55204868412, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Apr 12 21:22:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076655, encodeId=b81e20e665569, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Sep 03 23:22:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558034, encodeId=303e155803400, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Oct 09 10:22:00 CST 2015, time=2015-10-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2061129, encodeId=77fb206112943, content=<a href='/topic/show?id=ccfa6061407' target=_blank style='color:#2F92EE;'>#有效抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60614, encryptionId=ccfa6061407, topicName=有效抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Wed May 04 02:22:00 CST 2016, time=2016-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048684, encodeId=6c55204868412, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Apr 12 21:22:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076655, encodeId=b81e20e665569, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sat Sep 03 23:22:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558034, encodeId=303e155803400, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Fri Oct 09 10:22:00 CST 2015, time=2015-10-09, status=1, ipAttribution=)]
    2015-10-09 zsyan